Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
10 lessons
12mACE-031 is a discontinued myostatin-trapping drug sold online as a muscle builder. Its human trials were real, and so was the reason they stopped: a bleeding and blood-vessel signal traced to the one ligand the drug was never meant to catch. When an anti-doping laboratory tested fourteen products sold under the name, none of them contained ACE-031 at all.
11mFollistatin 344 is sold online as a muscle-building peptide. It is not a peptide: at 344 amino acids it is a protein. No published human trial has tested the injected product, the only follistatin-based drug to reach randomized trials grew muscle without improving function, and lab testing of black-market vials found most of them were not what the label said.
9mBefore you trust any peptide source, run the same checklist a pharmacist would: who is accountable, what was tested, by whom, for which batch, and what the paperwork still cannot tell you.
9mLilly has sued 11 retatrutide sellers, FDA has sent warning letters, and Australia's regulator found a 'retatrutide' vial full of semaglutide. Here's the timeline and what it means if you're considering retatrutide.
9mTesamorelin has one of the cleanest human-data stories in the peptide space. The new liver fat trial matters because it asks whether that signal extends into fatty liver disease.
8mGHK-Cu is moving beyond skin-care hype into a controlled wound-healing study. Here is how to read the Phase 2 trial without overclaiming the result.
8mMOTS-c is one of the most interesting mitochondrial peptides in 2026 because the question is finally shifting from mechanism to human outcomes.
8mBPC-157 finally has a registered human sports-injury study. The signal is important, but it is not proof yet. Here is how to read the trial without the hype.
8mRetatrutide is no longer just a weight-loss headline. Current 2026 trial records show researchers testing broader questions: pain, liver disease, cardiorenal risk, dose escalation, and lean-mass preservation.
8mProtect yourself by learning how to verify peptide quality, understand testing reports, and avoid dangerous products.
Also available at /blog for legacy links.